JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB312492

Alexa Fluor® 568 Anti-DDAH1 抗体 [EPR13922]

Alexa Fluor® 568 Anti-DDAH1 antibody [EPR13922]

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Recombinant Monoclonal DDAH1 antibody - conjugated to Alexa Fluor® 568.

別名を表示する

DDAH, DDAH1, DDAH-1, Dimethylarginine dimethylaminohydrolase 1, DDAHI, Dimethylargininase-1

関連する標識済み抗体及び組成の異なる製品 (10)

  • Unconjugated

    Anti-DDAH1 antibody [EPR13922]

  • 578 PE

    PE Anti-DDAH1 antibody [EPR13922]

  • 660 APC

    APC Anti-DDAH1 antibody [EPR13922]

  • 519 Alexa Fluor® 488

    Alexa Fluor® 488 Anti-DDAH1 antibody [EPR13922]

  • 665 Alexa Fluor® 647

    Alexa Fluor® 647 Anti-DDAH1 antibody [EPR13922]

  • HRP

    HRP Anti-DDAH1 antibody [EPR13922]

  • 617 Alexa Fluor® 594

    Alexa Fluor® 594 Anti-DDAH1 antibody [EPR13922]

  • 565 Alexa Fluor® 555

    Alexa Fluor® 555 Anti-DDAH1 antibody [EPR13922]

  • 775 Alexa Fluor® 750

    Alexa Fluor® 750 Anti-DDAH1 antibody [EPR13922]

  • Carrier free

    Anti-DDAH1 antibody [EPR13922] - BSA and Azide free

Key facts

宿主種

Rabbit

クローン性

Monoclonal

クローン番号

EPR13922

アイソタイプ

IgG

標識

Alexa Fluor® 568

励起波長/蛍光波長

Ex: 578nm, Em: 603nm

キャリアフリー

No

アプリケーション

Antibody Labelling, Target Binding Affinity

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

style
left-column
style
left-column

製品の詳細

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

style
left-column

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Protein A
バッファー組成
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
出荷温度
Blue Ice
短期保存期間
1-2 weeks
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle|Store in the dark
style
left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

The DDAH1 protein also known as dimethylarginine dimethylaminohydrolase 1 plays an important role in regulating nitric oxide (NO) production by metabolizing asymmetric dimethylarginine (ADMA) an inhibitor of nitric oxide synthase. This enzyme has a molecular mass of approximately 31 kDa and is widely expressed in various tissues including liver kidney and brain. It impacts the cardiovascular system by controlling ADMA levels which influence endothelial function and vascular tone.
Biological function summary

The actions of DDAH1 contribute significantly to cardiovascular homeostasis. Increased levels of ADMA resulting from impaired DDAH1 activity can lead to decreased NO production impacting cardiovascular health. DDAH1 does not form part of a complex but acts individually to affect NO synthesis through ADMA degradation. Understanding the biological roles of DDAH1 helps to appreciate how NO-mediated processes are tightly regulated within the body and its impact on vascular health.

Pathways

DDAH1 participates actively in the nitric oxide synthesis pathway. It modulates the levels of endothelial nitric oxide synthase (eNOS) by regulating ADMA which serves as an eNOS inhibitor. Through this pathway DDAH1 ensures a balance between NO production and regulation supporting vascular homeostasis and blood pressure control. DDAH1 shares functional connections with proteins like eNOS which are central to maintaining vascular health and preventing endothelial dysfunction.

Dysfunction of DDAH1 links closely to cardiovascular diseases and conditions like atherosclerosis. Elevated ADMA levels resulting from compromised DDAH1 activity contribute to endothelial dysfunction a precursor to atherosclerosis. The interconnected role with eNOS highlights DDAH1's importance in managing ADMA concentrations as imbalances can exacerbate disease progression. Investigating the influence of DDAH1 on these diseases offers insights into potential therapeutic targets for cardiovascular pathologies.
style
left-column
style
left-column

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

ターゲットの情報

Hydrolyzes N(G),N(G)-dimethyl-L-arginine (ADMA) and N(G)-monomethyl-L-arginine (MMA) which act as inhibitors of NOS. Has therefore a role in the regulation of nitric oxide generation.
See full target information DDAH1
style
left-column
style
left-column

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。
style
left-column
style
right-column

関連製品

Select an associated product type
Alternative Version
Primary Antibodies

AB240228

Anti-DDAH1 antibody [EPR13922] - BSA and Azide free

primary-antibodies

ddah1-antibody-epr13922-bsa-and-azide-free-ab240228

0

(0 reviews)

style
bg-slate-100

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com